SDCBP抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Human fetal brain tissue and hela cell, Primary antibody: P08946(SDCBP Antibody) at dilution 1/450, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 3 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P08946(SDCBP Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P08946(SDCBP Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The syndecan binding protein (SDCBP), also known as STOML2 or syntenin-1. is a cytosolic adaptor protein involved in cellular adhesion, membrane trafficking, and signal transduction. It contains two PDZ domains that enable interactions with the cytoplasmic tails of syndecans, a family of transmembrane heparan sulfate proteoglycans critical for extracellular matrix (ECM) communication. SDCBP mediates syndecan-dependent processes, including cytoskeletal organization, exosome biogenesis, and receptor tyrosine kinase signaling, by bridging syndecans to intracellular effectors like kinases or cytoskeletal proteins.

SDCBP antibodies are essential tools for studying its role in pathological conditions. Overexpression of SDCBP is linked to cancer progression, particularly in melanoma, breast, and colorectal cancers, where it promotes metastasis by enhancing ECM degradation and cell migration. It also interacts with viral proteins (e.g., HIV-1 Tat, HPV E6), facilitating viral entry or release. In neurodegenerative diseases, SDCBP regulates synaptic protein clustering and neuronal signaling.

These antibodies are widely used in Western blotting, immunoprecipitation, and immunofluorescence to detect SDCBP expression levels, localization, and binding partners in cell lysates or tissues. Monoclonal antibodies offer high specificity, while polyclonal antibodies may capture diverse isoforms. Validation often includes knockout/knockdown controls or overexpression assays. Researchers prioritize antibodies with minimal cross-reactivity to related PDZ-domain proteins (e.g., SDCBP2) to ensure accurate experimental outcomes in studying SDCBP's multifaceted roles.